3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
10
Lung Neoplasms
9
Colorectal Neoplasms
7
Breast Neoplasms
7
Prostatic Neoplasms
6
Rectal Neoplasms
3
Polycystic Ovary Syndrome
3
Neoplasm Metastasis
3
Colonic Neoplasms
3
Stomach Neoplasms
2
Smoking Cessation
2
Neoplastic Cells, Circulating
2
Motor Activity
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
2
Endometrial Neoplasms
2
Disease
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Venous Thromboembolism
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
1
Testicular Germ Cell Tumor
1
Stroke
1
Solitary Pulmonary Nodule
1
Skin Neoplasms
1
Sezary Syndrome
1
Interventions
pembrolizumab
37
Gemcitabine
29
Nivolumab
20
Cisplatin
19
atezolizumab
15
avelumab
14
Docetaxel
13
enfortumab vedotin
10
Carboplatin
10
durvalumab
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
8
Paclitaxel
7
Pemetrexed
6
toripalimab
5
cabozantinib
5
Fluorodeoxyglucose F18
5
sacituzumab govitecan
4
cabazitaxel
4
Taxes
4
vinflunine
3
tremelimumab
3
pemigatinib
3
X-Rays
3
Standard of Care
3
Specimen Handling
3
Radiotherapy
3
Mitomycin
3
Immunotherapy
3
Immunoglobulin G
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Transitional Cell
×
Hematologic Tests
×
Clear all
NCT04566029
2025-12-10
AMI
Centre Hospitalier Universitaire de NÄ«mes
Completed
40 enrolled